Baxter International (NYSE:BAX) Issues Q4 2024 Earnings Guidance

Baxter International (NYSE:BAX) updated its fourth quarter 2024 earnings guidance on Friday. The company provided EPS guidance of 0.770-0.810 for the period, compared to the consensus EPS estimate of 0.840. The company issued revenue guidance of -. Baxter International also updated its FY 2024 guidance to 2.900-2.940 EPS.

Baxter International Trading Down 0.2 %

BAX stock opened at $36.04 on Friday. The company has a quick ratio of 0.91, a current ratio of 1.40 and a debt-to-equity ratio of 1.35. The company has a market cap of $18.39 billion, a price-to-earnings ratio of 7.42, a PEG ratio of 1.21 and a beta of 0.60. The business has a fifty day simple moving average of $37.50 and a 200-day simple moving average of $36.16. Baxter International has a 52 week low of $32.48 and a 52 week high of $44.01.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.02. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.75 billion. Baxter International had a net margin of 16.51% and a return on equity of 18.06%. Baxter International’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.55 earnings per share. On average, equities research analysts expect that Baxter International will post 2.96 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on BAX shares. Morgan Stanley lowered shares of Baxter International from an “equal weight” rating to an “underweight” rating and cut their price objective for the stock from $39.00 to $30.00 in a report on Monday, July 15th. The Goldman Sachs Group boosted their price target on Baxter International from $36.00 to $40.00 and gave the stock a “neutral” rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. lowered their price objective on Baxter International from $44.00 to $42.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Wells Fargo & Company cut their target price on Baxter International from $44.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 7th. Finally, Citigroup raised their price target on shares of Baxter International from $38.00 to $40.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $41.20.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.